Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma

Summary

RATIONALE: Current therapies for adults with anaplastic astrocytomas that have not responded to standard therapy provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with anaplastic astrocytomas that have not responded to standard therapy. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with anaplastic astrocytomas that have not responded to standard therapy.

Timeline

Start

1996-03

Primary completion

2008-12

Completion

2009-12

Publications

• Background Burzynski SR, Janicki TJ, Burzynski GS. A phase II study of Antineoplastons A10 and AS2-1 injections in adult patients with recurrent anaplastic astrocytoma - Final report (Protocol BT-15). Cancer and Clinical Oncology 4(2): 13-23, 2015. DOI: http://dx.doi.org/10.5539/cco.v4n2p13

Drugs

Indications